APOE and Alzheimer disease: On the other hand, other studies reported no significant sex difference in the risk of developing mild cognitive impairment (MCI) and/or AD in older participants (aged between 55 and 85 years) that were carrying the APOE ε3/ε4 genotype (Neu et al., 2017).